- Home
- IMUX vs DTF Comparison
IMUX vs DTF Comparison
Compare IMUX & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- DTF
- Stock Information
- Founded
- IMUX 2016
- DTF 1991
- Country
- IMUX United States
- DTF United States
- Employees
- IMUX N/A
- DTF N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- DTF Investment Managers
- Sector
- IMUX Health Care
- DTF Finance
- Exchange
- IMUX Nasdaq
- DTF Nasdaq
- Market Cap
- IMUX 90.4M
- DTF 79.8M
- IPO Year
- IMUX N/A
- DTF N/A
- Fundamental
- Price
- IMUX $0.82
- DTF $11.38
- Analyst Decision
- IMUX Strong Buy
- DTF
- Analyst Count
- IMUX 5
- DTF 0
- Target Price
- IMUX $7.50
- DTF N/A
- AVG Volume (30 Days)
- IMUX 1.4M
- DTF 21.1K
- Earning Date
- IMUX 11-06-2025
- DTF 01-01-0001
- Dividend Yield
- IMUX N/A
- DTF 3.64%
- EPS Growth
- IMUX N/A
- DTF N/A
- EPS
- IMUX N/A
- DTF 0.44
- Revenue
- IMUX N/A
- DTF N/A
- Revenue This Year
- IMUX N/A
- DTF N/A
- Revenue Next Year
- IMUX N/A
- DTF N/A
- P/E Ratio
- IMUX N/A
- DTF $24.34
- Revenue Growth
- IMUX N/A
- DTF N/A
- 52 Week Low
- IMUX $0.56
- DTF $10.29
- 52 Week High
- IMUX $2.11
- DTF $11.19
- Technical
- Relative Strength Index (RSI)
- IMUX 45.68
- DTF 61.47
- Support Level
- IMUX $0.75
- DTF $11.32
- Resistance Level
- IMUX $0.90
- DTF $11.42
- Average True Range (ATR)
- IMUX 0.05
- DTF 0.07
- MACD
- IMUX -0.00
- DTF 0.00
- Stochastic Oscillator
- IMUX 47.20
- DTF 80.95
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.